New immune combo shows promise against stubborn lymphoma
NCT ID NCT03349450
First seen May 07, 2026 · Last updated Jun 13, 2026 · Updated 10 times
Summary
This study tested a combination of three drugs (DPX-Survivac, low-dose cyclophosphamide, and pembrolizumab) in 25 adults with diffuse large B-cell lymphoma that had come back or not responded to previous treatments. The goal was to see if the immune system could be boosted to shrink tumors. The treatment was given for up to one year, and participants were monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
London Health Sciences Centre
London, Ontario, N6A 5W9, Canada
-
McGill University Health Centre
Montreal, Quebec, Canada
-
Nova Scotia Health Authority: Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, B3H 2Y9, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
-
Sunnybrook Health Sciences Centre, Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
-
Tom Baker Cancer Centre - Alberta Health Services
Calgary, Alberta, Canada
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.